News & Updates

The use of liposomal irinotecan in combination with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX regimen) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP) in the first-line setting, according to the NAPOLI-3* trial presented at the ASCO GI 2023.

Rectal spacing with hyaluronic acid helps lessen rectal dosimetry and mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy (RT) for prostate cancer, according to a study.

Intravenous (IV) iron reduces the need for red blood cell (RBC) transfusions in patients with chemotherapy-induced anaemia (CIA), without any difference in adverse events (AEs), compared with oral iron or placebo in a new study.

Plasma Epstein-Barr virus (EBV) measurement, even when supplemented by imaging, cannot replace nasoendoscopy and biopsy in nasopharyngeal cancer (NPC) management during the COVID-19 pandemic, according to consensus recommendations by an international multidisciplinary group of experts.

The addition of blinatumomab to chemotherapy extended overall survival (OS) in adults with measurable residual disease (MRD)-negative B-lineage acute lymphoblastic leukaemia (ALL), according to results of the phase III ECOG-ACRIN E1910 trial.

Participating in an individualized rehabilitation program is beneficial to children with cancer, yielding significant gains in function without any adverse consequences, as reported in a study from Singapore.